There is a street in Philadelphia called Kensington Avenue. If you search for it online, the images that come back are unlike anything most people associate with a city in the world's wealthiest country. People slumped against walls, some standing but barely, bodies bent at impossible angles, eyes open but unseeing, skin covered in open wounds that do not heal. They are not dead. They are not asleep. They are somewhere in between, in a state that emergency responders, addiction medicine specialists, and the people who live on that street have all started calling the same thing: zombified.

The drug responsible for these scenes is not a new synthetic invention from a laboratory. It is a veterinary sedative called xylazine, designed to calm horses and cattle before surgery. Mixed with fentanyl, the synthetic opioid that has been killing Americans at a rate of over a hundred thousand a year, it creates a combination so dangerous that the White House declared it an emerging threat to the entire country in April 2023. It has since spread to 48 of 50 American states. It has been detected in the United Kingdom, Canada, Mexico, and multiple European countries. It has no antidote. It eats through human skin from the inside out. And most of the people who are on it do not even know they are taking it.

What Xylazine Actually Is

Xylazine is a central nervous system depressant, technically an alpha-2 adrenergic receptor agonist, that the US Food and Drug Administration approved decades ago for use in veterinary medicine. It was discovered as an antihypertensive agent in 1962 by Farbenfabriken Bayer in Leverkusen, West Germany. In human trials conducted in the 1960s it was found to depress the central nervous system so severely that further research for human use was discontinued, and it was marketed instead as a veterinary sedative. It has never been approved for human use by the FDA, the UK's MHRA, or the European Medicines Agency. It was never designed for human physiology.

When a human being is exposed to xylazine, the drug slows the heart rate, lowers blood pressure, depresses the central nervous system, and produces a heavy, incapacitating sedation. When combined with fentanyl, which is itself 80 to 100 times more potent than morphine, the two drugs interact in ways that are exponentially more dangerous than either alone. Research published in Frontiers in Pharmacology found that a nonlethal dose of xylazine produced an approximately 100-fold decrease in the estimated lethal dose of fentanyl, meaning xylazine makes fentanyl roughly a hundred times more deadly than it already is. Breathing slows to near-stopping levels. The heart rate drops. Blood pressure collapses. Death can occur within minutes of a high-dose combination.

The Problem That Makes It Worse Than Fentanyl Alone

The most terrifying fact about xylazine is not what it does to the body while the drug is active. It is what happens when someone overdoses on a fentanyl-xylazine combination and someone tries to save them.

Naloxone, the overdose reversal medication that has saved hundreds of thousands of lives in the opioid crisis, does not reverse the effects of xylazine. Because xylazine is not an opioid, naloxone cannot address it. This means that a first responder who arrives at an overdose scene, administers naloxone, and believes they have treated the situation, may have only partially helped. The fentanyl effects may be reversed. But the xylazine continues working, continuing to suppress breathing and heart function, continuing to drive the person toward death. Experts recommend that naloxone should still always be given in suspected overdoses because opioids are almost always present alongside xylazine and naloxone will not cause harm if opioids are not involved. But calling emergency services is essential because xylazine's effects continue after naloxone is administered and require additional medical intervention.

This single fact has transformed the landscape of overdose response in ways that emergency medicine specialists describe as a paradigm shift in the wrong direction. The naloxone distribution networks that public health agencies built over more than a decade were built around a drug that naloxone works on. With xylazine in the supply, that entire infrastructure is only partially effective.

The Wounds That Do Not Heal

Beyond the overdose risk, xylazine inflicts a second category of harm that is, in its own way, equally horrifying. Repeated xylazine use is associated with severe skin wounds, including open sores, ulcers, and abscesses. These are not simple injection site infections. They are necrotic wounds that spread across the body, including at sites that have never been injected, because xylazine constricts blood vessels so severely that it cuts off circulation to tissue, causing the tissue to die from the inside out. The wounds are large, deep, and extremely resistant to healing. They become infected easily and escalate rapidly to sepsis. They have caused the amputation of fingers, toes, hands, and limbs. Forensic expert Dr. John Thompson, chairman of psychiatry at Tulane University, put the long-term consequence plainly: imagine that in addition to the more than 100,000 drug overdose deaths, we now add to that a generation of young people missing fingers, toes, and limbs.

The wounds are also a barrier to medical care in ways that compound their danger. People who use drugs are already frequently reluctant to seek medical treatment due to experiences of stigma and discrimination in healthcare settings. The visible, severe, and unusual nature of xylazine wounds, combined with the media's heavy use of the word zombie, has intensified the stigma around seeking care, creating a situation where the people most urgently in need of wound treatment are the least likely to access it.

How It Spread and Why Nobody Knew

Xylazine did not appear in the global drug supply overnight. Its street name in Puerto Rico is anestesia de caballo, which translates as horse anaesthetic, and it was first detected in illicit drug markets there in 2001, after several xylazine-associated human deaths were reported at the Guerrero Correctional Institution in Aguadilla. From 2002 to 2008, its use was associated with a high number of inmate deaths at that facility. It spread into Philadelphia's drug market over the following decade and by 2021 was present in the majority of fentanyl seized in the city.

The reason drug dealers add xylazine to fentanyl is straightforward economics. Xylazine is cheap, and dealers use it to extend the effects of fentanyl, allowing them to dilute their product while maintaining or increasing the duration of the high. A DEA report published in 2024 noted that in 2023, 30 percent of all seized fentanyl powder contained xylazine. The drug is no longer a regional crisis concentrated in Philadelphia. It is a national and increasingly international public health emergency.

The Global Spread: Beyond America

The zombie drug is not a uniquely American crisis. It is a global one that is still in its early stages outside North America, but the trajectory in every country where it has appeared is the same: detection, alarm, inadequate regulatory response, and escalating harm.

In the United Kingdom, a 43-year-old man identified as Karl Warburton died in his home in May 2022. A study by researchers at King's College London, released in 2023, screened all drug-related deaths reported to the UK's National Programme on Substance Abuse Deaths and found xylazine present in his system alongside heroin, cocaine, and fentanyl. He was likely entirely unaware he was consuming the drug. The researchers described this as the first death associated with xylazine use reported in the UK and in Europe, and noted it indicated the entry of xylazine into the UK illicit drug supply. Subsequent research published in the journal Addiction in 2024 found broad evidence of xylazine across the UK illicit drug market beyond heroin supplies, triangulating findings from toxicology, drug testing services, and law enforcement data. In direct response, the UK government classified xylazine as a Class C drug under the Misuse of Drugs Act 1971 on January 15, 2025. Britain became the first European country to formally regulate the substance. Xylazine is not included in standard drug tests in the UK, meaning the true scale of its presence in the supply remains unknown and is almost certainly larger than detected cases suggest.

In Canada, xylazine has been detected in drug supplies in British Columbia, Ontario, and Quebec. Canada's opioid crisis has run parallel to America's for over a decade, with British Columbia in particular experiencing catastrophic overdose death rates. Researchers based in Vancouver, Philadelphia, and Chicago who co-authored a major commentary on xylazine stigma each reported witnessing xylazine's effects firsthand in their respective cities across North America, establishing that the drug's footprint extends well beyond the US northeast. Canadian politicians have already begun using the zombie drug framing in political discourse, with a federal Conservative health critic publicly describing people who use drugs as being in a zombie-like state in parliamentary debate, a development that addiction researchers cited as a direct example of stigmatising political language reaching the mainstream.

In Mexico, a study by the country's National Institute of Psychiatry, reported in the Times of India in April 2024, documented the unexpected presence of xylazine in drug supplies in Mexican border cities. The lead investigator, Clara Fleiz, told researchers: we were surprised to find xylazine, underscoring how rapidly the drug had moved through supply chains into a country where the opioid crisis was already severe. Mexico's health ministry issued a formal alert to health personnel and first responders about the potential adulteration of heroin and fentanyl with xylazine on April 8, 2024. Researchers studying xylazine's supply chain, including Dr. Joseph Friedman at the University of California, have noted that the drug is likely being manufactured internationally and smuggled across borders, with the southern US border identified as a key entry point for xylazine combined with illicitly manufactured fentanyl.

In Spain and Portugal, European drug monitoring bodies have flagged the detection of xylazine in drug samples, though at far lower prevalence than North America as of 2025. Germany has similarly begun monitoring its presence. The European Monitoring Centre for Drugs and Drug Addiction issued early warnings about xylazine's potential spread through European illicit opioid markets, noting that the shift in Europe's heroin supply following the Taliban's ban on poppy cultivation in Afghanistan was creating conditions in which synthetic opioids and adulterants like xylazine could penetrate markets that had historically been dominated by plant-based heroin.

In Australia, a powerful new synthetic opioid called nitazene, up to 1,000 times stronger than morphine, emerged in Adelaide's street drug supply in 2025, suggesting that the global phenomenon of increasingly potent and dangerous drug adulterants is not confined to xylazine or to the Western hemisphere. The pattern, of a drug supply that continuously evolves toward greater lethality in response to enforcement pressure and market incentives, is a global one.

The Evolution: When Xylazine Was Replaced by Something Worse

Just as public health agencies were beginning to develop coherent responses to xylazine, the drug supply evolved again. During the last four months of 2024, medetomidine, another non-opioid sedative not approved for human use, replaced xylazine as the most common drug adulterant in Philadelphia's illegal opioid supply, detected in 72 percent of illegal opioid samples tested during that period, while xylazine detection decreased from 98 percent to 31 percent of samples.

Medetomidine is not a safer alternative to xylazine. It is 10 to 20 times more potent. During September 2024 and January 2025, 165 patients at three Philadelphia health systems were hospitalised for fentanyl withdrawal complicated by profound autonomic dysfunction, including severe hypertension and tachycardia, associated with medetomidine exposure. The withdrawal syndrome was resistant to medications that had previously been effective. Emergency medicine physicians were encountering patients whose withdrawal symptoms they had no established protocol to treat, because the drug causing those symptoms had entered the supply faster than medical understanding of it could develop.

This is the most important and most frightening dimension of the zombie drug crisis in 2025 and 2026: it is not static. The drug supply is adaptive. Pennsylvania regulated xylazine more tightly and the supply responded by switching to medetomidine. The harm reduction infrastructure was left, once again, without adequate tools for the new threat.

The Scale of the Crisis

In 2023, there were 107,543 drug overdose deaths in the United States, with synthetic opioids, primarily illicit fentanyl, as the main cause. That number represents more American deaths in a single year than the entirety of the Vietnam War. In Philadelphia alone, 2023 saw 1,315 overdose deaths, the second highest in the city's history, with 83 percent involving fentanyl. The ongoing opioid epidemic is projected to claim an estimated 1.2 million additional lives by 2029 unless significant policy reforms are implemented.

In the UK, drug-related deaths have remained at historically high levels, with Scotland consistently recording the highest drug death rate in Europe. Canada's British Columbia province declared a public health emergency over overdose deaths in 2016 that has never been lifted. The global scale of synthetic opioid harm is not yet fully captured in international mortality data because many countries lack the toxicological testing infrastructure to detect xylazine and medetomidine in post-mortem examinations. What is being counted is likely a significant undercount of the actual toll.

The Hope: A Vaccine in Development

Amid the uniformly grim picture of the zombie drug's spread, one piece of genuinely hopeful science deserves attention. Researchers at Scripps Research Institute published a study in Chemical Communications in April 2024 announcing the development of a vaccine designed to block the effects of xylazine's toxicity. The vaccine works by training the immune system to recognise and attack the drug before it can bind to receptors in the brain and body. In animal studies, the vaccine reversed the symptoms of xylazine overdose in rodents, significantly increasing movement in mice given xylazine after ten minutes and improving breathing. Two of the three formulations tested showed a strong ability to stop xylazine from crossing the blood-brain barrier and reaching its receptors. A provisional patent has been filed. The team's next goal is a bifunctional antibody that will reverse both fentanyl and xylazine toxicity simultaneously, something that naloxone cannot do, offering a potential future in which a single treatment addresses the combined threat. The research is at an early stage and human trials remain years away, but it represents the first targeted scientific intervention against xylazine beyond supportive care.

The Stigma Problem

The term zombie drug is not neutral. It does real damage to real people. Research published in a peer-reviewed addiction journal found that wide-scale media framing of xylazine as the zombie drug has increased stigma toward people who use drugs, with the zombie analogy reifying a subhuman status for a population already profoundly vulnerable to medical neglect. Zombies are cinematically depicted as soulless, dangerous, and required to be killed off for public safety. Applying that framing to people in the grip of a medical condition they often did not choose and frequently were not even aware of choosing is not neutral description. It is dehumanisation, and dehumanisation has measurable consequences: people with xylazine wounds who seek medical care report contemptuous treatment, and clinicians exposed to months of zombie framing carry that framing into the consultation room, where it compromises the quality and compassion of care in ways that can be the difference between a wound that heals and a sepsis that kills.

What Is Being Done and What Is Not

The White House declared fentanyl mixed with xylazine an emerging threat in April 2023. A National Response Plan was released in July 2023. In 2025, the DEA seized more than 47 million fentanyl-laced fake pills and nearly 10,000 pounds of fentanyl powder, equivalent to more than 369 million lethal doses. The UK made xylazine a Class C drug in January 2025. Mexico issued health alerts. These responses are real. They are not proportionate to the scale of what they are responding to.

What is not being done at adequate scale is the structural work that addiction medicine specialists consistently identify as necessary: expanded access to medication-assisted treatment, comprehensive wound care programmes that do not require abstinence as a precondition, and xylazine test strip distribution at the scale the problem demands. Xylazine remains not a controlled substance under the US Controlled Substances Act. The medetomidine shift demonstrated exactly what happens when one substance is regulated patchwork-style in a national drug supply: the market simply adopts the unregulated alternative.

What This Crisis Tells Us

The zombie drug crisis is not primarily a story about a strange veterinary sedative. It is a story about what happens when societies, across the United States, the United Kingdom, Canada, Mexico, and now Europe, fail repeatedly and at enormous scale to address addiction as a public health issue rather than a criminal justice one, and then watch their drug supplies become more and more lethal in response to each inadequate intervention.

The people on Kensington Avenue are not zombies. Neither is the man in Birmingham whose body was found with xylazine in 2022. Neither are the people in the supervised consumption sites in Vancouver, in the harm reduction services in Lisbon, in the clinics in Mexico City. They are human beings in the grip of a condition that is medical in its nature, that is being made worse by a drug supply that treats their lives as an acceptable cost of doing business, and that is being inadequately served by policy environments that still, in 2026, have not fully committed to treating addiction with the seriousness of resource and infrastructure that they would bring to any other medical emergency killing this many people, in this many countries, every single year.

The drug is called the zombie drug because of what it does to the people who take it. What it actually reveals is not something monstrous about them. It reveals something about the systems, everywhere in the world where it has spread, that allowed it to get this far.

References:

1. DEA, Reports Widespread Threat of Fentanyl Mixed with Xylazine — https://www.dea.gov
2. CDC, What You Should Know About Xylazine — https://www.cdc.gov
3. NIDA, Xylazine Research Topics — https://nida.nih.gov
4. PMC, The Xylazine-Fentanyl Nexus: A Public Health Emergency — https://pmc.ncbi.nlm.nih.gov
5. PMC, Tranq-Dope Overdose and Mortality: Lethality Induced by Fentanyl and Xylazine — https://pmc.ncbi.nlm.nih.gov
6. CDC MMWR, Suspected Medetomidine Withdrawal Syndrome, Philadelphia September 2024 to January 2025 — https://www.cdc.gov
7. Psychology Today, The Zombie Drugs: Xylazine and Medetomidine, April 2025 — https://www.psychologytoday.com
8. ScienceDirect, Media Framing Xylazine as a Zombie Drug Is Amplifying Stigma onto People Who Use Drugs — https://www.sciencedirect.com
9. ScienceDirect, Zombie Drugs: Dehumanising News Frames and Public Stigma Towards People Who Use Drugs — https://www.sciencedirect.com
10. Euronews, Xylazine: What to Know About the Flesh-Eating Zombie Drug Spreading from the US to Europe — https://www.euronews.com
11. PMC, Presumptive Tests for Xylazine: A Computer Vision Approach, 2025 — https://pmc.ncbi.nlm.nih.gov
12. ScienceDirect, Xylazine Addiction Turning Humans to Zombies: Fact or Myth? — https://www.sciencedirect.com
13. Scripps Research Institute, Developing a Vaccine for the Zombie Drug Xylazine, April 2024 — https://www.scripps.edu
14. ScienceDaily, Developing a Vaccine for the Zombie Drug Xylazine — https://www.sciencedaily.com
15. End Time Headlines, Doctors Warn That Zombie Drug Smuggled Across Southern Border Is Spreading Across America, March 2025 — https://endtimeheadlines.org
16. Wikipedia, Xylazine — https://en.wikipedia.org
17. BAART Programs, Xylazine and Fentanyl Overdose Risks and Dangers, February 2025 — https://baartprograms.com

.   .   .